Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study.

Endometriosis is a benign condition characterized by the presence of ectopic endometrial tissue. Our study investigated the effect of endometriosis on the risk of endometrial cancer (EC) and the prognosis of endometriosis-associated EC. In our study, 197,196 patients with endometriosis and without a previous diagnosis of EC were compared with 6,455,556 females encountering health services for examinations, with body mass index (BMI) data, and without endometriosis or EC. A propensity score generated 197,141 matched pairs. In the endometriosis cohort, 875 cases of EC were seen, whereas 558 were in the control group: the hazard ratio (HR) was 1.56 (95% CI 1.40-1.73, p  < 0.001). Women with endometriosis were more likely to develop invasive endometrioid ( p  = 0.005) and clear cell ( p  < 0.001) EC. There was no difference in overall survival between endometriosis-associated EC and EC without endometriosis. Our epidemiological findings were consistent with the evidence of an association between endometriosis and EC.
Competing Interests: A.F.: Financial interests, personal, advisory board: AstraZeneca, GSK, Janssen; financial interests, personal, invited speaker: GSK, Clovis Oncology, AstraZeneca. U.F.F. De Giorgi: Financial interests, personal, advisory board: Pfizer, BMS, MSD, PharmaMar, Astellas, Bayer, Ipsen, Novartis, EISAI, Janssen; financial interests, personal, invited speaker: Roche, BMS, Clovis Oncology, AstraZeneca; financial interests, institutional, research grant: AstraZeneca, Sanofi, Roche. F.R. and G.H.I.: Financial interests, personal, full or part-time employment: TriNexT, Inc.
(© 2024 The Author(s).)